257 related articles for article (PubMed ID: 24159374)
1. Selective Delivery of an Anticancer Drug with Aptamer-Functionalized Liposomes to Breast Cancer Cells
Xing H; Tang L; Yang X; Hwang K; Wang W; Yin Q; Wong NY; Dobrucki LW; Yasui N; Katzenellenbogen JA; Helferich WG; Cheng J; Lu Y
J Mater Chem B; 2013 Oct; 1(39):5288-5297. PubMed ID: 24159374
[TBL] [Abstract][Full Text] [Related]
2. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance.
Liao ZX; Chuang EY; Lin CC; Ho YC; Lin KJ; Cheng PY; Chen KJ; Wei HJ; Sung HW
J Control Release; 2015 Jun; 208():42-51. PubMed ID: 25637705
[TBL] [Abstract][Full Text] [Related]
3. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
[TBL] [Abstract][Full Text] [Related]
4. A novel theranostic system of AS1411 aptamer-functionalized albumin nanoparticles loaded on iron oxide and gold nanoparticles for doxorubicin delivery.
Baneshi M; Dadfarnia S; Shabani AMH; Sabbagh SK; Haghgoo S; Bardania H
Int J Pharm; 2019 Jun; 564():145-152. PubMed ID: 30978484
[TBL] [Abstract][Full Text] [Related]
5. Aptamer-integrated α-Gal liposomes as bispecific agents to trigger immune response for killing tumor cells.
Hong S; Ding P; Luo Y; Gao T; Zhang Y; Pei R
J Biomed Mater Res A; 2019 Jun; 107(6):1176-1183. PubMed ID: 30650243
[TBL] [Abstract][Full Text] [Related]
6. Aptamer-functionalized quercetin thermosensitive liposomes for targeting drug delivery and antitumor therapy.
Li J; Gao Y; Liu S; Cai J; Zhang Q; Li K; Liu Z; Shi M; Wang J; Cui H
Biomed Mater; 2022 Sep; 17(6):. PubMed ID: 36001994
[TBL] [Abstract][Full Text] [Related]
7. Aptamer-Aptamer Chimera for Targeted Delivery and ATP-Responsive Release of Doxorubicin into Cancer Cells.
Esawi E; Alshaer W; Mahmoud IS; Alqudah DA; Azab B; Awidi A
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884745
[TBL] [Abstract][Full Text] [Related]
8. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
9. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
Mosafer J; Mokhtarzadeh A
Curr Drug Deliv; 2018; 15(9):1323-1329. PubMed ID: 30039760
[TBL] [Abstract][Full Text] [Related]
10. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
[TBL] [Abstract][Full Text] [Related]
11. Aptamer-functionalized liposomes for targeted cancer therapy.
Moosavian SA; Sahebkar A
Cancer Lett; 2019 Apr; 448():144-154. PubMed ID: 30763718
[TBL] [Abstract][Full Text] [Related]
12. AS1411 aptamer-functionalized exosomes in the targeted delivery of doxorubicin in fighting colorectal cancer.
Hosseini NF; Amini R; Ramezani M; Saidijam M; Hashemi SM; Najafi R
Biomed Pharmacother; 2022 Nov; 155():113690. PubMed ID: 36099793
[TBL] [Abstract][Full Text] [Related]
13. Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment.
Liang X; Wang Y; Shi H; Dong M; Han H; Li Q
Int J Nanomedicine; 2021; 16():2569-2584. PubMed ID: 33833512
[TBL] [Abstract][Full Text] [Related]
14. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
[TBL] [Abstract][Full Text] [Related]
15. Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo.
Alibolandi M; Taghdisi SM; Ramezani P; Hosseini Shamili F; Farzad SA; Abnous K; Ramezani M
Int J Pharm; 2017 Mar; 519(1-2):352-364. PubMed ID: 28126548
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of doxorubicin and therapeutic FOXM1 aptamer to tumor cells using gold nanoparticles modified with AS1411 and ATP aptamers.
Abdollahzade A; Rahimi H; Yaghoobi E; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
Iran J Basic Med Sci; 2023; 26(10):1177-1187. PubMed ID: 37736517
[TBL] [Abstract][Full Text] [Related]
17. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas.
Li L; Hou J; Liu X; Guo Y; Wu Y; Zhang L; Yang Z
Biomaterials; 2014 Apr; 35(12):3840-50. PubMed ID: 24486214
[TBL] [Abstract][Full Text] [Related]
18. A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.
Gray BP; McGuire MJ; Brown KC
PLoS One; 2013; 8(8):e72938. PubMed ID: 24009717
[TBL] [Abstract][Full Text] [Related]
19. A nuclear targeted Dox-aptamer loaded liposome delivery platform for the circumvention of drug resistance in breast cancer.
Li X; Wu X; Yang H; Li L; Ye Z; Rao Y
Biomed Pharmacother; 2019 Sep; 117():109072. PubMed ID: 31202169
[TBL] [Abstract][Full Text] [Related]
20. Anti-nucleolin Aptamer as a Boom in Rehabilitation of Breast Cancer.
Janani SK; Dhanabal SP; Sureshkumar R; Nikitha Upadhyayula SS
Curr Pharm Des; 2022; 28(38):3114-3126. PubMed ID: 36173049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
